Notes The above financial summary may not be comparable across the periods presented due to the changes in the Group structure. For changes in the accounting policies, adoption of new and/or revised accounting standards, as well as changes in presentation of financial statements for the current financial year, only the comparative figures for the previous year are restated to conform with the requirements arising from the said changes or adoption. Comparative figures for the previous year are restated, where applicable, upon the completion of the Purchase Price Allocation on the Group’s acquisitions of subsidiaries as required under MFRS 3, Business Combinations. 1. Labs comprise the Group’s diagnostic laboratory business. In the table above, prior to FY2022, Labs was classified as part of the Singapore, Malaysia, India, and Türkiye and Europe Hospital and Healthcare business segment. 2. Others comprise mainly corporate offices as well as other investment holding entities. 3. Arises from the application of MFRS 129, Financial Reporting in Hyperinflationary Economies for component entities whose functional currency is the Turkish Lira. 4. Being earnings before interest, tax, depreciation, amortisation, exchange differences, share of results of associates and joint ventures and other non-operational items. 5. Being net assets attributable to ordinary shareholders (excluding non-controlling interests). 6. Being net assets attributable to ordinary shareholders (excluding non-controlling interests) less goodwill and intangible assets. 7. Being PATMI for the year over average of equity attributable to owners of the Company as at year-end and beginning of the year. 8. Debt includes loans and borrowings as well as lease liabilities and bank overdrafts. FY2019 FY2020 FY2021 FY2022 FY2023 A. Income Statement (RM Million) Revenue by Strategic Business Units Singapore 4,289.8 3,886.5 5,033.3 4,912.8 5,573.0 Malaysia 2,331.1 2,187.1 2,727.2 3,073.7 3,683.6 India 3,320.9 2,655.8 3,728.8 3,175.1 3,554.5 Greater China 604.6 662.4 876.9 998.4 1,306.8 Türkiye and Europe 3,764.7 3,462.2 4,347.2 4,455.3 5,945.1 Southeast Asia 190.8 138.4 – – – Hospital and Healthcare 14,501.9 12,992.4 16,713.4 16,615.3 20,063.0 IMU Health 259.0 248.7 257.6 260.8 53.9 Labs total revenue – – – 1,662.0 1,664.9 Less: Labs inter-segment revenue – – – (602.6) (685.4) Labs1 – – – 1,059.4 979.5 Others2 12.1 8.5 7.6 5.0 5.7 14,773.0 13,249.6 16,978.6 17,940.5 21,102.1 PLife REIT total revenue 347.9 367.0 370.7 376.2 407.8 PLife REIT inter-segment revenue (208.4) (212.0) (217.5) (226.7) (254.7) PLife REIT 139.5 155.0 153.2 149.5 153.1 14,912.5 13,404.6 17,131.8 18,090.0 21,255.2 Hyperinflationary adjustment3 – – – (101.3) (320.4) Total 14,912.5 13,404.6 17,131.8 17,988.7 20,934.8 EBITDA4 by Strategic Business Units Singapore 1,475.1 1,359.5 1,693.0 1,483.9 1,626.7 Malaysia 675.2 555.9 760.1 846.8 937.3 India 360.0 200.5 664.5 492.3 600.4 Greater China (175.5) (146.5) (69.6) (60.3) 74.5 Türkiye and Europe 853.5 796.1 1,198.9 1,058.2 1,249.2 Southeast Asia 69.1 45.6 (0.3) (0.3) (1.8) Hospital and Healthcare 3,257.4 2,811.1 4,246.6 3,820.6 4,486.3 IMU Health 87.2 75.7 86.7 84.8 13.0 Labs1 – – – 369.3 345.4 Others2 (112.0) (107.4) (185.6) (170.7) (120.6) Eliminations – – – 9.2 (0.1) 3,232.6 2,779.4 4,147.7 4,113.2 4,724.0 PLife REIT 294.4 308.9 349.9 278.4 325.8 Eliminations (209.3) (212.0) (218.2) (234.3) (263.6) 3,317.7 2,876.3 4,279.4 4,157.3 4,786.2 Hyperinflationary adjustment3 – – – (106.2) (142.2) Total 3,317.7 2,876.3 4,279.4 4,051.1 4,644.0 Profit After Tax and Minority Interest (“PATMI”) Including Exceptional Items 551.5 288.9 1,862.5 1,548.4 2,951.9 Excluding Exceptional Items 920.7 715.3 1,594.8 1,380.7 1,279.2 B. Financial Position (RM Million) Total Assets 45,053.3 44,534.3 45,510.3 48,467.5 50,192.2 Net Borrowings 6,385.0 7,441.0 5,856.0 7,170.4 7,670.6 Equity attributable to Owners of the Company 22,339.5 21,739.8 22,424.9 26,192.0 29,105.5 C. Financial Ratios Basic Earnings per Share (sen) Including Exceptional Items 5.28 2.27 20.20 17.00 33.52 Excluding Exceptional Items 9.49 7.13 17.15 15.09 14.53 Net Assets5 per Share (RM) 2.55 2.48 2.55 2.97 3.30 Net Tangible Assets6 per Share (RM) 0.88 0.87 0.94 1.16 1.35 Return on Equity7 (%) Including Exceptional Items 2.5% 1.3% 8.4% 6.5% 10.7% Excluding Exceptional Items 4.2% 3.2% 7.2% 5.8% 4.6% Return on Total Assets (%) Including Exceptional Items 1.2% 0.6% 4.1% 3.2% 5.9% Excluding Exceptional Items 2.0% 1.6% 3.5% 2.8% 2.5% Net Debt Equity Ratio8 (times) 0.23 0.28 0.21 0.25 0.24 Annual Report 2023 13
RkJQdWJsaXNoZXIy NDgzMzc=